Persistent Activation of Innate Immunity in Patients with Primary Antibody Deficiencies

Figure 3

The intensity of expression of surface markers on PMN in four PAD patients before and after (5-7 months) the initiation of immunoglobulin replacement treatment. (a) CD64, (b) CD10, (c) CD18, and (d) CD11b at basal state and (e) CD16 and (f) CD11b after whole-blood incubation with LPS. Each line in the plot corresponds to data of each patient.